Marinus Pharmaceuticals Stock Price Prediction

MRNS Stock  USD 0.32  0.01  3.03%   
The relative strength index (RSI) of Marinus Pharmaceuticals' share price is below 30 at this time. This indicates that the stock is becoming oversold or undervalued. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Marinus Pharmaceuticals, making its price go up or down.

Oversold Vs Overbought

25

 
Oversold
 
Overbought
The successful prediction of Marinus Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Marinus Pharmaceuticals and does not consider all of the tangible or intangible factors available from Marinus Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Marinus Pharmaceuticals, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Marinus Pharmaceuticals' stock price prediction:
EPS Estimate Next Quarter
(0.28)
EPS Estimate Current Year
(2.00)
EPS Estimate Next Year
(0.75)
Wall Street Target Price
1.4667
EPS Estimate Current Quarter
(0.41)
Using Marinus Pharmaceuticals hype-based prediction, you can estimate the value of Marinus Pharmaceuticals from the perspective of Marinus Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Marinus Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Marinus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Marinus Pharmaceuticals after-hype prediction price

    
  USD 0.33  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Marinus Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.
Intrinsic
Valuation
LowRealHigh
0.275.4618.10
Details
Naive
Forecast
LowNextHigh
0.010.5713.22
Details
10 Analysts
Consensus
LowTargetHigh
19.0220.9023.20
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.51-0.5-0.49
Details

Marinus Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Marinus Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Marinus Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Marinus Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Marinus Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Marinus Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Marinus Pharmaceuticals' historical news coverage. Marinus Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.02 and 12.97, respectively. We have considered Marinus Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.32
0.33
After-hype Price
12.97
Upside
Marinus Pharmaceuticals is very risky at this time. Analysis and calculation of next after-hype price of Marinus Pharmaceuticals is based on 3 months time horizon.

Marinus Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Marinus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marinus Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Marinus Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.65 
12.73
  0.12 
  0.13 
7 Events / Month
15 Events / Month
In about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.32
0.33
3.91 
6,700  
Notes

Marinus Pharmaceuticals Hype Timeline

Marinus Pharmaceuticals is now traded for 0.32. The entity has historical hype elasticity of -0.12, and average elasticity to hype of competition of -0.13. Marinus is estimated to increase in value after the next headline, with the price projected to jump to 0.33 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 3.91%, whereas the daily expected return is now at -0.65%. The volatility of related hype on Marinus Pharmaceuticals is about 6552.21%, with the expected price after the next announcement by competition of 0.19. Marinus Pharmaceuticals currently holds 110.36 M in liabilities with Debt to Equity (D/E) ratio of 0.88, which is about average as compared to similar companies. Given the investment horizon of 90 days the next estimated press release will be in about 7 days.
Check out Marinus Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.

Marinus Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Marinus Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Marinus Pharmaceuticals' future price movements. Getting to know how Marinus Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Marinus Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
AKROAkero Therapeutics(0.28)9 per month 2.66  0.08  5.23 (4.45) 13.37 
TERNTerns Pharmaceuticals 0.30 8 per month 0.00 (0.09) 5.68 (5.96) 34.09 
MDGLMadrigal Pharmaceuticals 3.47 9 per month 2.09  0.10  5.17 (3.96) 30.27 
INZYInozyme Pharma(0.03)8 per month 0.00 (0.27) 5.68 (7.92) 16.62 
VKTXViking Therapeutics(6.17)10 per month 0.00 (0.06) 6.24 (8.05) 34.61 
ETNB89bio Inc(0.11)9 per month 3.29  0.0002  5.19 (6.35) 27.43 
CABACabaletta Bio(0.42)6 per month 0.00 (0.26) 7.82 (10.89) 30.64 
MIRMMirum Pharmaceuticals(1.72)9 per month 2.35  0.01  4.24 (4.31) 12.25 
AMLXAmylyx Pharmaceuticals 0.02 11 per month 4.02  0.24  10.06 (6.13) 33.56 
ABOSAcumen Pharmaceuticals(0.10)4 per month 0.00 (0.06) 7.52 (6.67) 28.07 
XFORX4 Pharmaceuticals 0.02 7 per month 0.00 (0.08) 6.90 (10.61) 62.35 
ELYMEliem Therapeutics 0.25 4 per month 0.00 (0.20) 6.21 (9.35) 34.87 
IKNAIkena Oncology(0.05)4 per month 1.39 (0.07) 1.81 (1.74) 13.50 
OVIDOvid Therapeutics 0.02 7 per month 0.00 (0.07) 5.93 (6.25) 19.20 
CNTBConnect Biopharma Holdings 0.02 5 per month 5.38  0.01  12.12 (9.01) 48.67 
EWTXEdgewise Therapeutics 0.32 10 per month 2.85  0.11  6.65 (4.70) 61.02 
THRXTheseus Pharmaceuticals 0.14 2 per month 0.00 (0.06) 11.75 (8.57) 90.33 
PMVPPmv Pharmaceuticals(0.1)3 per month 2.01 (0.01) 3.75 (3.64) 13.98 
CGEMCullinan Oncology LLC 1.25 10 per month 0.00 (0.17) 5.88 (7.24) 17.85 
ELVNEnliven Therapeutics(0.55)9 per month 2.04  0  5.84 (4.07) 12.96 
IMRXImmuneering Corp(0.36)6 per month 5.21  0.13  15.50 (8.68) 60.06 

Marinus Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Marinus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Marinus using various technical indicators. When you analyze Marinus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Marinus Pharmaceuticals Predictive Indicators

The successful prediction of Marinus Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Marinus Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Marinus Pharmaceuticals based on analysis of Marinus Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Marinus Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Marinus Pharmaceuticals's related companies.
 2021 2023 2024 (projected)
Days Sales Outstanding75.7844.7542.51
PTB Ratio8.1534.8536.59

Story Coverage note for Marinus Pharmaceuticals

The number of cover stories for Marinus Pharmaceuticals depends on current market conditions and Marinus Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Marinus Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Marinus Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Marinus Pharmaceuticals Short Properties

Marinus Pharmaceuticals' future price predictability will typically decrease when Marinus Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Marinus Pharmaceuticals often depends not only on the future outlook of the potential Marinus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Marinus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding53.7 M
Cash And Short Term Investments150.3 M

Additional Tools for Marinus Stock Analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.